Cantor Fitzgerald analyst Steve Seedhouse initiated coverage of Apellis (APLS) with an Overweight rating and $44 price target
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on APLS:
- Market Challenges and Revenue Dynamics Impacting Apellis Pharmaceuticals: A Hold Rating Analysis
- Hold Rating on Apellis Pharmaceuticals Amid Competitive Pressure from Astellas’ Izervay
- Buy Rating Affirmed for Apellis Pharmaceuticals Amid Market Expansion and Growth Prospects
- Apellis price target lowered to $21 from $24 at RBC Capital
- Apellis Pharmaceuticals Elects Craig Wheeler to Board